je.st
news
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
2016-03-25 15:53:27| Biotech - Topix.net
The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni.
Tags: pay
million
drug
ordered
Category:Biotechnology and Pharmaceuticals